Virax Biolabs has launched the distribution of human papillomavirus (HPV) test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union.
The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.
Virax's Chairman of the Board and CEO, James Foster commented: "We are excited to expand our ViraxClear line of tests into an additional significant area of concern. These tests will cover more genotypes, have shorter processing times and lower costs than the currently available HPV tests in Europe. As we are able to supply around 200,000 of these tests per week, we have a significant opportunity to capture some market share."
HPV is one of the most prevalent sexually transmitted infections in the developed world. HPV is also the primary cause of cervical cancer in women with around 33,000 cases and 15,000 deaths annually in the EU, according to the European Centre for Disease Prevention and Control. Globally the World Health Organization estimates that HPV causes over 600,000 cases of cervical cancer annually.
Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases. Learn more about the company at www.viraxbiolabs.com.
